As of November 6, 2026, Organogenesis Holdings Inc. is a publicly traded company (Nasdaq: ORGO). The largest holder reporting an active stake on Schedule 13D is Glenn H. Nussdorf, a director, at 9.7%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Soleus Capital Master Fund, L.P. (7.9%) (Schedule 13D/A, November 3, 2025).
Is this your company?
About to sign with, pay or invest in Organogenesis Holdings Inc.? See the free Snapshot first.
Free to see. No signup.
Is Organogenesis Holdings Inc. a real, registered company?
- Organogenesis Holdings Inc. files with the SEC under CIK 1661181 (its SEC filings).
- Its shares are listed under the ticker ORGO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Canton, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Organogenesis Holdings Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Soleus Capital Master Fund, L.P. (filed 2026-02-12).
Who are Organogenesis Holdings Inc.'s owners and officers?
Organogenesis Holdings Inc.: incorporated in Delaware; business address in Canton, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-02-17).
Officers and directors, each with the role and the filing that names them:
- : Director (Form D, 2024-11-27)
- : Director (Form D, 2024-11-27)
- : Director (Form D, 2024-11-27)
- : Director (Form D, 2024-11-27)
- : Director (Form D, 2024-11-27)
- : Director (Form D, 2024-11-27)
- : Executive Officer, Director (Form D, 2024-11-27)
- : Director (Form D, 2024-11-27)
- : Director (Form D, 2024-11-27)
- : Director (Form D, 2024-11-27)
- : Director (Form D, 2024-11-27)
- : Executive Officer (Form D, 2024-11-27)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-02-17 | Mathew P. Arens | 3.06% |
| Schedule 13G/A, 2026-02-12 | Soleus Capital Master Fund, L.P. | 7.9% |
| Schedule 13D/A, 2025-11-03 | Glenn H. Nussdorf | 9.7% |
| Schedule 13G, 2025-08-14 | Mathew P. Arens | 6.55% |
Questions about who owns Organogenesis Holdings Inc.
Who owns Organogenesis Holdings Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Organogenesis Holdings Inc.: Glenn H. Nussdorf (9.7%, Schedule 13D/A, filed 2025-11-03) and Soleus Capital Master Fund, L.P. (7.9%, Schedule 13G/A, filed 2026-02-12).
Who are the largest shareholders of Organogenesis Holdings Inc.?
By the share each holder's latest filing reports, the largest holders of Organogenesis Holdings Inc. on this page are Glenn H. Nussdorf (9.7%) and Soleus Capital Master Fund, L.P. (7.9%).
When did Glenn H. Nussdorf buy into Organogenesis Holdings Inc.?
The filings give report dates, not purchase dates. The earliest filing from Glenn H. Nussdorf on this page is the Schedule 13D/A, filed 2025-11-03, reporting 9.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Organogenesis Holdings Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Organogenesis Holdings Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Organogenesis Holdings Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Organogenesis Holdings Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 153,256,206 shares, 102,170,804 held directly and 51,085,402 indirectly, on a joint filing (Form 4, 2025-01-13).
- , a 10% owner: 153,256,206 shares, 102,170,804 held directly and 51,085,402 indirectly, on a joint filing (Form 4, 2025-01-13).
- GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, a 10% owner: 153,256,206 shares, 102,170,804 held directly and 51,085,402 indirectly, on a joint filing (Form 4, 2025-01-13).
- , a 10% owner: 153,256,206 shares, 102,170,804 held directly and 51,085,402 indirectly, on a joint filing (Form 4, 2025-01-13).
- , a 10% owner: 153,256,206 shares, 102,170,804 held directly and 51,085,402 indirectly, on a joint filing (Form 4, 2025-01-13).
Shares outstanding: 129,801,720 as of 2026-10-30, from the company's latest SEC cover page.
How much has Organogenesis Holdings Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-11-27 | $130M | $130M |
Keep reading
More on Organogenesis Holdings Inc. and the records around it.
Organogenesis Holdings Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), Neogenomics, Inc. (Aug 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/organogenesis